GenoMed, Inc. Obtains American Diabetes Association Approval.

Business Editors & Health/Medical Writers

SARASOTA, Fla.--(BUSINESS WIRE)--Dec. 19, 2001

GenoMed Inc. ("the Company" or "GenoMed") (Pink Sheets:GMED), a St. Louis, Missouri based medical genomics biotechnology company, announced today that it has obtained approval from the American Diabetes Association ("ADA") to utilize its bank of DNA samples from patients with type 2 diabetes.

The ADA's diabetes DNA bank, the "G.E.N.N.I.D." collection, is the world's largest shareable repository of DNA from patients with type 2 diabetes. The ADA has assembled the collection at a cost exceeding $10,000,000.

During the next 12 months, GenoMed intends to utilize the G.E.N.N.I.D. collection to identify disease-predisposition genes for type 2 diabetes. GenoMed expects to apply data obtained through its research of the collection to substantiate the utility of the Company's scientific approach. The Company's ultimate objective will then be to develop clinical treatments against type 2 diabetes.

"While the ADA cannot endorse the activities of any single company, the ADA is keenly aware that many important research advances in the field of diabetes will come from industry," stated Matt Petersen, the Director of Research Programs at the American Diabetes Association's headquarters in Alexandria, Virginia.

"We are pleased to have obtained approval from the ADA to access this valuable resource. I am confident that the ADA appreciates the capital, the time, and the effort that GenoMed is allocating to the research and clinical treatment of diabetes," stated GenoMed's Chief Medical Officer, Dr. David Moskowitz.

About GenoMed

GenoMed was founded with the sole purpose of translating knowledge of disease genes into better patient outcomes as rapidly and as safely as possible. The Company's business model specifically links improved patient outcomes to Company revenues through clinical treatment and genetic diagnoses of diseases.

For additional information please visit http://www.genomedics.com and/or contact Craig Hall @ [phone] or email at [e-mail].

This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those statements pertaining to the benefits that may be potentially derived from the Company's use of the ADA's G.E.N.N.I.D collection. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties. Among other things, competition from existing or new competitors will impact our business; our research and development is subject to economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not undertake, and specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.